Recent News
- Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium
- Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome
- Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital
- Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
- Radius Health Expands Non-US Market Footprint for TYMLOS
- Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
- Radius Files Definitive Proxy and Mails Letter to Stockholders
- Radius Health Update on Abaloparatide Transdermal System
- Radius Adds Industry Veterans Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors
- Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology